{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:52:32Z","timestamp":1793508752310,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Overactive bladder (OAB) affects 5\u201312% of children and is associated with urgency, frequency, and incontinence, often leading to psychosocial distress. Antimuscarinics are widely used but limited by systemic side effects. Mirabegron, a \u03b23-adrenoceptor agonist, may offer better tolerability. This review evaluated available evidence comparing mirabegron and solifenacin in pediatric OAB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following PRISMA guidelines (PROSPERO: CRD420251129236), we searched PubMed, Scopus, Web of Science, and the Cochrane Library through September 2025 for studies directly comparing mirabegron and solifenacin in children\u2009\u2264\u200918 years with non-neurogenic OAB. Two reviewers independently screened studies, extracted data, and assessed quality. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three studies (246 children; 116 mirabegron, 130 solifenacin) met inclusion criteria. Pooled analysis showed no significant difference in treatment response between groups (RR\u2009=\u20091.11, 95% CI: 0.92\u20131.33;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.28; I\u00b2 = 58%). Mirabegron was associated with significantly fewer adverse events (RR\u2009=\u20090.44, 95% CI: 0.28\u20130.70;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0004; I\u00b2 = 0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mirabegron and solifenacin demonstrate comparable efficacy in pediatric OAB, with mirabegron suggesting a more favorable short-term safety profile. These preliminary findings require confirmation in larger, long-term trials with standardized outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-026-02155-9","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T05:53:43Z","timestamp":1776491623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of mirabegron versus solifenacin in the treatment of overactive bladder in children: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8966-3908","authenticated-orcid":false,"given":"Mostafa","family":"Shaheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Mohamed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A.","family":"Draz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro K.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elghattas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toqa","family":"Elbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iyad","family":"Walid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnim","family":"Tarboush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa Mohamed","family":"Elkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah Adel","family":"Nofal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Samaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"2155_CR1","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.5489\/CUAJ.4337","volume":"11","author":"S Ramsay","year":"2017","unstructured":"Ramsay S, Bolduc S. Overactive bladder in children. Can Urol Association J. 2017;11:S74. https:\/\/doi.org\/10.5489\/CUAJ.4337.","journal-title":"Can Urol Association J"},{"key":"2155_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5213\/INJ.2244228.114","volume":"27","author":"J Shim","year":"2023","unstructured":"Shim J, Oh MM. Updates of Overactive Bladder in Pediatrics. Int Neurourol J. 2023;27:3. https:\/\/doi.org\/10.5213\/INJ.2244228.114.","journal-title":"Int Neurourol J"},{"key":"2155_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3339\/CHIKD.2015.19.1.1","volume":"19","author":"SJ Jeong","year":"2015","unstructured":"Jeong SJ. Fecal Retention in Overactive Bladder (OAB) in Children: Perspective of a Pediatric Gastroenterologist. Child Kidney Dis. 2015;19:1\u20137. https:\/\/doi.org\/10.3339\/CHIKD.2015.19.1.1.","journal-title":"Child Kidney Dis"},{"key":"2155_CR4","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/NRUROL.2016.152;SUBJMETA","volume":"13","author":"I Franco","year":"2016","unstructured":"Franco I. Overactive bladder in children. Nat Rev Urol. 2016;13:520\u201332. https:\/\/doi.org\/10.1038\/NRUROL.2016.152;SUBJMETA.","journal-title":"Nat Rev Urol"},{"key":"2155_CR5","doi-asserted-by":"publisher","unstructured":"Al-Rimawi SM, Alrimawi I, Ibrahim MM, Oleimat B, Elayan AM, Khatatbeh H, et al. The Effect of Intravesical Injection of Botulinum Toxin A (BTX-A) on Quality of Life of Pediatrics Diagnosed With Overactive Bladder: A Quasi-Experimental Study. Sage Open Pediatr. 2025;12. https:\/\/doi.org\/10.1177\/30502225251346341.","DOI":"10.1177\/30502225251346341"},{"key":"2155_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5489\/CUAJ.1356","volume":"8","author":"G Nadeau","year":"2014","unstructured":"Nadeau G, Schr\u00f6der A, Moore K, Genois L, Lamontagne P, Hamel M, et al. Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study. Can Urol Association J. 2014;8:118. https:\/\/doi.org\/10.5489\/CUAJ.1356.","journal-title":"Can Urol Association J"},{"key":"2155_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/0009922816641366","volume":"56","author":"AC Kinlaw","year":"2016","unstructured":"Kinlaw AC, Jonsson Funk M, Steiner MJ, Conover MM, Pate V, Wu JM. Trends in Pharmacotherapy for Bladder Dysfunction Among Children in the United States, 2000\u20132013. Clin Pediatr (Phila). 2016;56:55. https:\/\/doi.org\/10.1177\/0009922816641366.","journal-title":"Clin Pediatr (Phila)"},{"key":"2155_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41598-020-65989-9;SUBJMETA","volume":"10","author":"N Cebron Lipovec","year":"2020","unstructured":"Cebron Lipovec N, Jazbar J, Kos M. Anticholinergic Burden in Children, Adults and Older Adults in Slovenia: A Nationwide Database Study. Sci Rep. 2020;10:1\u20138. https:\/\/doi.org\/10.1038\/S41598-020-65989-9;SUBJMETA.","journal-title":"Sci Rep"},{"key":"2155_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5213\/INJ.1734850.425","volume":"21","author":"KE Andersson","year":"2017","unstructured":"Andersson KE. On the Site and Mechanism of Action of \u03b23-Adrenoceptor Agonists in the Bladder. Int Neurourol J. 2017;21:6. https:\/\/doi.org\/10.5213\/INJ.1734850.425.","journal-title":"Int Neurourol J"},{"key":"2155_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4274\/JUS.GALENOS.2019.2533","volume":"6","author":"\u00d6 Acar","year":"2019","unstructured":"Acar \u00d6, Erton ML, Tarcan T, Acar \u00d6, Erton ML, Tarcan T. Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make? J Urol Surg. 2019;6:85\u201392. https:\/\/doi.org\/10.4274\/JUS.GALENOS.2019.2533.","journal-title":"J Urol Surg"},{"key":"2155_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/IJCP.12194","volume":"67","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Khullar V, Van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67:619. https:\/\/doi.org\/10.1111\/IJCP.12194.","journal-title":"Int J Clin Pract"},{"key":"2155_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","volume":"63","author":"CR Chapple","year":"2013","unstructured":"Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b23-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63:296\u2013305. https:\/\/doi.org\/10.1016\/j.eururo.2012.10.048.","journal-title":"Eur Urol"},{"key":"2155_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","volume":"63","author":"V Khullar","year":"2013","unstructured":"Khullar V, Amarenco G, Angulo JC, Cambronero J, H\u00f8ye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder: Results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283\u201395. https:\/\/doi.org\/10.1016\/j.eururo.2012.10.016.","journal-title":"Eur Urol"},{"key":"2155_CR14","unstructured":"1 Recommendations. | Mirabegron for treating symptoms of overactive bladder | Guidance | NICE n.d. https:\/\/www.nice.org.uk\/guidance\/TA290\/chapter\/1-Recommendations. (accessed September 25, 2025)."},{"key":"2155_CR15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/JU.0000000000002361","volume":"207","author":"JK Kim","year":"2022","unstructured":"Kim JK, De Jesus MJ, Lee MJ, Dos Santos J, Dy JS, Ming JM, et al. \u03b23-Adrenoceptor Agonist for the Treatment of Bladder Dysfunction in Children: A Systematic Review and Meta-Analysis. J Urol. 2022;207:524\u201333. https:\/\/doi.org\/10.1097\/JU.0000000000002361.","journal-title":"J Urol"},{"key":"2155_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1159\/000515992","volume":"105","author":"MG Soliman","year":"2021","unstructured":"Soliman MG, E-ASE-GOMRAAA-RAR, El-Abd AS. Mirabegron versus Solifenacin in Children with Overactive Bladder: prospective Randomized Single-Blind Controlled Trial. Urol Int. 2021;105:1011\u20137. https:\/\/doi.org\/10.1159\/000515992.","journal-title":"Urol Int"},{"key":"2155_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4111\/ICU.20200380","volume":"62","author":"SC Kim","year":"2021","unstructured":"Kim SC, Park M, Chae C, Yoon JH, Kwon T, Park S, et al. Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study. Investig Clin Urol. 2021;62:317\u201323. https:\/\/doi.org\/10.4111\/ICU.20200380.","journal-title":"Investig Clin Urol"},{"key":"2155_CR18","doi-asserted-by":"publisher","first-page":"S829","DOI":"10.1016\/S0302-2838(24)00691-2","volume":"85","author":"IE-HAAEALMDM Mansour","year":"2024","unstructured":"Mansour I, Laymon M, Abdelhalim A, Dawaba MS, El-Hefnawy AS. Efficacy and safety of mirabegron compared to solifenacin in treatment of non-neurogenic overactive bladder in children: a randomized controlled trial. Int Braz J Urol. 2025;51. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2024.0425.","journal-title":"Eur Urol"},{"key":"2155_CR19","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372. https:\/\/doi.org\/10.1136\/BMJ.N71.","DOI":"10.1136\/BMJ.N71"},{"key":"2155_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13643-016-0384-4\/FIGURES\/6","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:1\u201310. https:\/\/doi.org\/10.1186\/S13643-016-0384-4\/FIGURES\/6.","journal-title":"Syst Rev"},{"key":"2155_CR21","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/CL2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Reviews. 2022;18:e1230. https:\/\/doi.org\/10.1002\/CL2.1230.","journal-title":"Campbell Syst Reviews"},{"key":"2155_CR22","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366. https:\/\/doi.org\/10.1136\/BMJ.L4898.","DOI":"10.1136\/BMJ.L4898"},{"key":"2155_CR23","unstructured":"Ottawa Hospital Research Institute n.d. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. (accessed September 20, 2025)."},{"key":"2155_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/BMJ.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360. https:\/\/doi.org\/10.1136\/BMJ.327.7414.557.","journal-title":"BMJ"},{"key":"2155_CR25","unstructured":"RevMan. accessed September 22, n.d. 2025. https:\/\/revman.cochrane.org\/myReviews."},{"key":"2155_CR26","doi-asserted-by":"publisher","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","DOI":"10.1186\/1471-2288-14-135"},{"key":"2155_CR27","doi-asserted-by":"publisher","unstructured":"Jessen AS, Hagstroem S, Borch L. Comparison and characteristics of children successfully treated for daytime urinary incontinence. J Pediatr Urol. 2022;18:24.e1-24.e9. https:\/\/doi.org\/10.1016\/j.jpurol.2021.11.013.","DOI":"10.1016\/j.jpurol.2021.11.013"},{"key":"2155_CR28","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1590\/S1677-5538.IBJU.2015.0579","volume":"42","author":"AS Sousa","year":"2016","unstructured":"Sousa AS, Veiga ML, Braga AAN, Carvalho MC, Junior UB. Enuresis and overactive bladder in children: what is the relationship between these two conditions? Int Braz J Urol. 2016;42:798\u2013802. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2015.0579.","journal-title":"Int Braz J Urol"},{"key":"2155_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/NAU.23863","volume":"38","author":"J Wang","year":"2019","unstructured":"Wang J, Zhou Z, Cui Y, Li Y, Yuan H, Gao Z, et al. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn. 2019;38:22\u201330. https:\/\/doi.org\/10.1002\/NAU.23863.","journal-title":"Neurourol Urodyn"},{"key":"2155_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/1756287215589250","volume":"7","author":"JE Batista","year":"2015","unstructured":"Batista JE, K\u00f6lbl H, Herschorn S, Rechberger T, Cambronero J, Halaska M, et al. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol. 2015;7:167. https:\/\/doi.org\/10.1177\/1756287215589250.","journal-title":"Ther Adv Urol"},{"key":"2155_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000445808","volume":"97","author":"C Vecchioli Scaldazza","year":"2016","unstructured":"Vecchioli Scaldazza C, Morosetti C. Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study. Urol Int. 2016;97:325\u20139. https:\/\/doi.org\/10.1159\/000445808.","journal-title":"Urol Int"},{"key":"2155_CR32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.55519\/JAMC-02-11795","volume":"35","author":"MN Jamil","year":"2023","unstructured":"Jamil MN, Irum S, Islam EU. Comparison Of Solifenacin And Mirabegron For The Treatment Of Overactive Bladder. J Ayub Med Coll Abbottabad. 2023;35:298\u2013300. https:\/\/doi.org\/10.55519\/JAMC-02-11795.","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"2155_CR33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1586\/14750708.3.4.485","volume":"3","author":"J-J Wyndaele","year":"2006","unstructured":"Wyndaele J-J. DRUG PROFILE Solifenacin: a new drug for the treatment of overactive bladder and detrusor overactivity. Therapy. 2006;3:485\u201394. https:\/\/doi.org\/10.1586\/14750708.3.4.485.","journal-title":"Therapy"},{"key":"2155_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41598-022-16487-7;SUBJMETA","volume":"12","author":"EG West","year":"2022","unstructured":"West EG, McDermott C, Chess-Williams R, Sellers DJ. Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice. Sci Rep. 2022;12:1\u201312. https:\/\/doi.org\/10.1038\/S41598-022-16487-7;SUBJMETA.","journal-title":"Sci Rep"},{"key":"2155_CR35","doi-asserted-by":"publisher","unstructured":"Glassberg KI, Van Batavia JP, Combs AJ. Can children with either overactive bladder or dysfunctional voiding transition from one into the other: Are both part of a single entity? J Pediatr Urol. 2016;12:217.e1-217.e8. https:\/\/doi.org\/10.1016\/j.jpurol.2016.05.024.","DOI":"10.1016\/j.jpurol.2016.05.024"},{"key":"2155_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/iju.15065","volume":"30","author":"M\u0130 D\u00f6nmez","year":"2023","unstructured":"D\u00f6nmez M\u0130, Selvi I, Dereli E, \u00d6zg\u00fcr K, Oktar T, Ziylan O. Maintenance biofeedback therapy for dysfunctional voiding: Does every child need it? Int J Urol. 2023;30:83\u201390. https:\/\/doi.org\/10.1111\/iju.15065.","journal-title":"Int J Urol"},{"key":"2155_CR37","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/J.EURURO.2018.03.020","volume":"74","author":"C Kelleher","year":"2018","unstructured":"Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aball\u00e9a S, et al. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. Eur Urol. 2018;74:324\u201333. https:\/\/doi.org\/10.1016\/J.EURURO.2018.03.020.","journal-title":"Eur Urol"},{"key":"2155_CR38","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/J.EURURO.2013.11.010","volume":"65","author":"K Maman","year":"2014","unstructured":"Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, et al. Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison. Eur Urol. 2014;65:755\u201365. https:\/\/doi.org\/10.1016\/J.EURURO.2013.11.010.","journal-title":"Eur Urol"},{"key":"2155_CR39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/S11255-013-0509-9\/FIGURES\/5","volume":"46","author":"Y Cui","year":"2014","unstructured":"Cui Y, Zong H, Yang C, Yan H, Zhang Y. The efficacy and safety of mirabegron in treating OAB: A systematic review and meta-analysis of phase III trials. Int Urol Nephrol. 2014;46:275\u201384. https:\/\/doi.org\/10.1007\/S11255-013-0509-9\/FIGURES\/5.","journal-title":"Int Urol Nephrol"},{"key":"2155_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4103\/PICR.PICR_166_23","volume":"15","author":"MO Raj","year":"2024","unstructured":"Raj MO, Jose J, Paul F, Sreedharan S, Uthaman N. Therapeutic effectiveness and adverse drug reactions of mirabegron versus solifenacin in the treatment of overactive bladder syndrome. Perspect Clin Res. 2024;15:147\u201351. https:\/\/doi.org\/10.4103\/PICR.PICR_166_23.","journal-title":"Perspect Clin Res"},{"key":"2155_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.eururo.2016.02.007","volume":"70","author":"A-S Blais","year":"2016","unstructured":"Blais A-S, Nadeau G, Moore K, Genois L, Bolduc S. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder. Eur Urol. 2016;70:9\u201313. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.007.","journal-title":"Eur Urol"},{"key":"2155_CR42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40272-021-00452-4","volume":"23","author":"SJ Keam","year":"2021","unstructured":"Keam SJ, Mirabegron. Pediatric First Approval. Paediatr Drugs. 2021;23:411\u20135. https:\/\/doi.org\/10.1007\/s40272-021-00452-4.","journal-title":"Paediatr Drugs"},{"key":"2155_CR43","unstructured":"FDA approves VESIcare for. pediatric use | Contemporary Pediatrics n.d. https:\/\/www.contemporarypediatrics.com\/view\/fda-approves-vesicare-pediatric-use?utm_source=chatgpt.com. (accessed March 3, 2026)."},{"key":"2155_CR44","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/nau.20507","volume":"27","author":"KM Giramonti","year":"2008","unstructured":"Giramonti KM, Kogan BA, Halpern LF. The effects of anticholinergic drugs on attention span and short-term memory skills in children. Neurourol Urodyn. 2008;27:315\u20138. https:\/\/doi.org\/10.1002\/nau.20507.","journal-title":"Neurourol Urodyn"},{"key":"2155_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41598-020-80211-6","volume":"11","author":"E Ghezzi","year":"2021","unstructured":"Ghezzi E, Chan M, Kalisch Ellett LM, Ross TJ, Richardson K, Ho JN, et al. The effects of anticholinergic medications on cognition in children: a systematic review and meta-analysis. Sci Rep. 2021;11:219. https:\/\/doi.org\/10.1038\/s41598-020-80211-6.","journal-title":"Sci Rep"},{"key":"2155_CR46","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.juro.2016.11.101","volume":"197","author":"F Morin","year":"2017","unstructured":"Morin F, Blais AS, Nadeau G, Moore KN, Genois L, Bolduc S. Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study. J Urol. 2017;197:1158\u201363. https:\/\/doi.org\/10.1016\/j.juro.2016.11.101.","journal-title":"J Urol"},{"key":"2155_CR47","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/bju.13882","volume":"120","author":"S Herschorn","year":"2017","unstructured":"Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120:562\u201375. https:\/\/doi.org\/10.1111\/bju.13882.","journal-title":"BJU Int"},{"key":"2155_CR48","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","volume":"67","author":"P Abrams","year":"2015","unstructured":"Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (symphony). Eur Urol. 2015;67:577\u201388. https:\/\/doi.org\/10.1016\/j.eururo.2014.02.012.","journal-title":"Eur Urol"},{"key":"2155_CR49","doi-asserted-by":"publisher","first-page":"e45612","DOI":"10.7759\/cureus.45612","volume":"15","author":"S Kumar","year":"2023","unstructured":"Kumar S, Tiwari V, Chaurasia DK, Kumar S, Mishra S. A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder. Cureus. 2023;15:e45612. https:\/\/doi.org\/10.7759\/cureus.45612.","journal-title":"Cureus"},{"key":"2155_CR50","doi-asserted-by":"publisher","unstructured":"Tan DJY, Weninger J, Goyal A. Mirabegron in Overactive Bladder and Its Role in Exit Strategy After Botulinum Toxin Treatment in Children. Front Pediatr. 2022;9. https:\/\/doi.org\/10.3389\/fped.2021.801517.","DOI":"10.3389\/fped.2021.801517"},{"key":"2155_CR51","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s00345-025-05799-8","volume":"43","author":"B Peyronnet","year":"2025","unstructured":"Peyronnet B, Brucker BM, De Nunzio C, Gratzke C, Heesakkers J, Michel MC, et al. Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes. World J Urol. 2025;43:514. https:\/\/doi.org\/10.1007\/s00345-025-05799-8.","journal-title":"World J Urol"},{"key":"2155_CR52","doi-asserted-by":"publisher","unstructured":"Kato T, Mizuno K, Nishio H, Yasui T, Hayashi Y. Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report. J Med Case Rep 2021 15:1 2021;15:86\u2013. https:\/\/doi.org\/10.1186\/s13256-020-02564-w.","DOI":"10.1186\/s13256-020-02564-w"},{"key":"2155_CR53","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jpurol.2022.07.012","volume":"18","author":"T Kitta","year":"2022","unstructured":"Kitta T, Chiba H, Kon M, Higuchi M, Kusakabe N, Ouchi M, et al. Urodynamic evaluation of the efficacy of vibegron, a new \u03b23-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder. J Pediatr Urol. 2022;18:563\u20139. https:\/\/doi.org\/10.1016\/j.jpurol.2022.07.012.","journal-title":"J Pediatr Urol"},{"key":"2155_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/JU.0000000000003763","volume":"211","author":"H Chen","year":"2024","unstructured":"Chen H, Zhang Z, Wu S, Zhang D, Zhong X, Liu X, et al. Efficacy and Safety of High-Dose Vitamin D Supplementation vs Solifenacin or Standard Urotherapy for Overactive Bladder Dry in Children: A Randomized Clinical Trial. J Urol. 2024;211:26\u201336. https:\/\/doi.org\/10.1097\/JU.0000000000003763.","journal-title":"J Urol"},{"key":"2155_CR55","doi-asserted-by":"publisher","unstructured":"Chen H, Zhang Z, Zhang Q, Wang C, Liu Z, Ye Z, et al. Efficacy of high-dose vitamin D supplementation vs. solifenacin or standard urotherapy for overactive bladder dry in children: a secondary analysis of a randomized clinical trial. World J Urol. 2024;42. https:\/\/doi.org\/10.1007\/s00345-024-05296-4.","DOI":"10.1007\/s00345-024-05296-4"},{"key":"2155_CR56","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1590\/S1677-5538.IBJU.2021.0645","volume":"48","author":"B \u00d6z\u00e7ift","year":"2022","unstructured":"\u00d6z\u00e7ift B, Micoogullari U. The effect of vitamin D deficiency in children with overactive bladder related urinary incontinence. Int Braz j Urol. 2022;48:316\u201325. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2021.0645.","journal-title":"Int Braz j Urol"},{"key":"2155_CR57","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/RRU.S124981","volume":"9","author":"LL de Wall","year":"2017","unstructured":"de Wall LL, Heesakkers JPFA. Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome. Res Rep Urol. 2017;9:145\u201357. https:\/\/doi.org\/10.2147\/RRU.S124981.","journal-title":"Res Rep Urol"},{"key":"2155_CR58","doi-asserted-by":"publisher","unstructured":"Lambregts AP, Nieuwhof-Leppink AJ, Klijn AJ, Schroeder RPJ. Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladder. J Pediatr Urol. 2022;18:351.e1-351.e8. https:\/\/doi.org\/10.1016\/j.jpurol.2022.02.007.","DOI":"10.1016\/j.jpurol.2022.02.007"},{"key":"2155_CR59","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/jpm13040616","volume":"13","author":"YH Fan","year":"2023","unstructured":"Fan YH, Kuo HC. Efficacy of Intravesical Botulinum Toxin A Injection in the Treatment of Refractory Overactive Bladder in Children. J Personalized Med 2023. 2023;13:13. https:\/\/doi.org\/10.3390\/jpm13040616.","journal-title":"J Personalized Med 2023"},{"key":"2155_CR60","doi-asserted-by":"publisher","first-page":"1407009","DOI":"10.3389\/fped.2024.1407009","volume":"12","author":"BT Frainey","year":"2024","unstructured":"Frainey BT, Clayton DB. OnabotulinumtoxinA is now an important tool for managing pediatric neurogenic lower urinary tract dysfunction. Front Pediatr. 2024;12:1407009. https:\/\/doi.org\/10.3389\/fped.2024.1407009.","journal-title":"Front Pediatr"},{"key":"2155_CR61","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5213\/INJ.2040354.177","volume":"24","author":"YH Jiang","year":"2020","unstructured":"Jiang YH, Chen SF, Kuo HC. Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction. Int Neurourol J. 2020;24:301\u201312. https:\/\/doi.org\/10.5213\/INJ.2040354.177.","journal-title":"Int Neurourol J"},{"key":"2155_CR62","doi-asserted-by":"publisher","first-page":"9062","DOI":"10.3390\/ijerph19159062","volume":"19","author":"LL De Wall","year":"2022","unstructured":"De Wall LL, Bekker AP, Oomen L, Janssen VACT, Kortmann BBM, Heesakkers JPFA, et al. Posterior Tibial Nerve Stimulation in Children with Lower Urinary Tract Dysfunction: A Mixed-Methods Analysis of Experiences, Quality of Life and Treatment Effect. Int J Environ Res Public Health. 2022;19:9062. https:\/\/doi.org\/10.3390\/ijerph19159062.","journal-title":"Int J Environ Res Public Health"},{"key":"2155_CR63","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/nau.24575","volume":"40","author":"R Jafarov","year":"2021","unstructured":"Jafarov R, Ceyhan E, Kahraman O, Ceylan T, Dikmen ZG, Tekgul S, et al. Efficacy of transcutaneous posterior tibial nerve stimulation in children with functional voiding disorders. Neurourol Urodyn. 2021;40:404\u201311. https:\/\/doi.org\/10.1002\/nau.24575.","journal-title":"Neurourol Urodyn"},{"key":"2155_CR64","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5213\/inj.1938232.116","volume":"24","author":"H Cui","year":"2020","unstructured":"Cui H, Yao Y, Xu Z, Gao Z, Wu J, Zhou Z, et al. Role of Transcutaneous Electrical Nerve Stimulation in Treating Children With Overactive Bladder From Pooled Analysis of 8 Randomized Controlled Trials. Int Neurourol J. 2020;24:84\u201394. https:\/\/doi.org\/10.5213\/inj.1938232.116.","journal-title":"Int Neurourol J"},{"key":"2155_CR65","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12887-025-05460-8","volume":"25","author":"KN Lin","year":"2025","unstructured":"Lin KN, Yin BQ, Xu LY, Chen ZQ, Cui X. Clinical efficacy of transcutaneous pelvic floor magnetic stimulation combined with urination training in the treatment of overactive bladder in children. BMC Pediatr. 2025;25:110. https:\/\/doi.org\/10.1186\/s12887-025-05460-8.","journal-title":"BMC Pediatr"},{"key":"2155_CR66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11884-024-00759-1","volume":"19","author":"M Malallah","year":"2024","unstructured":"Malallah M, Cameron A, Sack B. The Evidence for Implantable Sacral Neuromodulation in Pediatric Voiding Dysfunction. Curr Bladder Dysfunct Rep 2024. 2024;19:3. https:\/\/doi.org\/10.1007\/s11884-024-00759-1.","journal-title":"Curr Bladder Dysfunct Rep 2024"},{"key":"2155_CR67","doi-asserted-by":"publisher","first-page":"820816","DOI":"10.1155\/2011\/820816","volume":"2011","author":"A Athanasopoulos","year":"2011","unstructured":"Athanasopoulos A, Giannitsas K. An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder. Adv Urol. 2011;2011:820816. https:\/\/doi.org\/10.1155\/2011\/820816.","journal-title":"Adv Urol"}],"updated-by":[{"DOI":"10.1186\/s12894-026-02179-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000}}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02155-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:32:05Z","timestamp":1780039925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-026-02155-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2155"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02155-9","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In the Methods section concerning the description of the Cochrane Risk of Bias tool version 2 (RoB 2) refers to seven domains, whereas RoB 2 evaluates five domains.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12894-026-02179-1","URL":"https:\/\/doi.org\/10.1186\/s12894-026-02179-1","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}